Advertisement
Advertisement

ZVRA

ZVRA logo

Zevra Therapeutics, Inc. Common Stock

8.61
USD
Sponsored
+0.25
+2.93%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

8.59

-0.02
-0.17%

ZVRA Earnings Reports

Positive Surprise Ratio

ZVRA beat 19 of 40 last estimates.

48%

Next Report

Date of Next Report
Mar 09, 2026
Estimate for Q4 25 (Revenue/ EPS)
$28.61M
/
$0.05
Implied change from Q3 25 (Revenue/ EPS)
+9.78%
/
-600.00%
Implied change from Q4 24 (Revenue/ EPS)
+137.58%
/
-107.25%

Zevra Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 05, 2025, ZVRA reported earnings of -0.01 USD per share (EPS) for Q3 25, beating the estimate of -0.03 USD, resulting in a 71.99% surprise. Revenue reached 26.06 million, compared to an expected 27.16 million, with a -4.04% difference. The market reacted with a -9.73% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of 0.05 USD, with revenue projected to reach 28.61 million USD, implying an decrease of -600.00% EPS, and increase of 9.78% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Zevra Therapeutics, Inc. Common Stock reported EPS of -$0.01, beating estimates by 71.99%, and revenue of $26.06M, -4.04% below expectations.
The stock price moved down -9.73%, changed from $10.07 before the earnings release to $9.09 the day after.
The next earning report is scheduled for Mar 09, 2026.
Based on 10 analysts, Zevra Therapeutics, Inc. Common Stock is expected to report EPS of $0.05 and revenue of $28.61M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement